Other · developed by Novo Nordisk
NNC4005-001 is given subcutaneously as a single ascending dose in a trial in fatty liver disease, specifically non-alcoholic fatty liver disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07214870 | Phase 1 | Fatty Liver Disease | Active not recruiting | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fatty Liver Disease
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →